证券日报网讯瑞茂通（600180）11月26日在互动平台回答投资者提问时表示，公司毛利率水平符合大宗 商品供应链行业情况，同时公司会结合自身的发展阶段和战略安排在市场布局、经营品类、业务模式上 不断拓展与创新，通过国际国内双市场的开拓、多品类经营矩阵的建立不断提高公司的毛利率水平。 ...

丨证券研究报告丨 行业研究丨点评报告丨纺织品、服装与奢侈品 [Table_Title] 望远镜系列 28 之 On FY2025Q3 经营跟踪：收 入表现超预期，持续上调全年指引 报告要点 [Table_Summary] FY2025Q3（2025/07/01-2025/09/30）On 实现营收 7.9 亿 CHF，表现优于市场预期（彭博一 致预期 7.7 亿 CHF），固定汇率下同比+34.5%。毛利率同比+5.1pct 至 65.7%，主要受益于品 牌强劲增长、运营效率改善和汇率正向影响，其中约 2pct 一次性贡献为低预期成本带来。调整 后 EBITDA 同比+49.8%至 1.8 亿 CHF，调整后 EBITDA 利润率为 22.6%。归母净利润同比 +290%至 1.2 亿 CHF，归母净利率同比+10.2pct 至 15.0%。 分析师及联系人 [Table_Author] 于旭辉 柯睿 SAC：S0490518020002 SAC：S0490524110001 SFC：BUU942 请阅读最后评级说明和重要声明 %% %% %% %% 1）分地区：美洲/EMEA/亚太地区营收分别同比增长 21 ...

投资者活动基本情况 活动类别及时空信息 2025年11月20日下午14:00-16:00，楚天科技股份有限公司（以下简称"楚天科技"）以"特定对象调研+现 场参观"形式接待了机构投资者调研。活动地点位于公司会议室，通过厂区参观与会议室座谈相结合的 方式，就公司经营发展等议题与机构代表展开交流。 参与机构及接待人员 本次调研参与机构包括康曼德资本、中泰证券、人保资产、国信证券共4家机构。楚天科技方面由董事 会秘书黄玉婷、证券事务代表周德伟负责接待并回应提问。 核心交流要点解读 海外市场拓展：五大区域布局显效 进入快速增长通道 在海外市场拓展策略方面，公司表示目前主要聚焦东南亚、中东非、欧洲、美洲、印度新澳五大区域， 依托行业稀缺的整体解决方案能力、高性价比服务及渠道优势推动高质量销售与服务落地。 据介绍，经过近3-5年的持续战略布局、资源投入与业务积淀，公司海外业务已进入快速增长通道。其 中，中东非、东南亚区域已取得阶段性突破性成果，欧洲、美洲区域后续订单与业绩有望实现逐步突 破。 毛利率展望：2025年预计维持30%左右 未来有望稳步提升 关于毛利率水平，公司披露2025年综合毛利率预计维持在30%左右。长期 ...

编号：2025-011 | | 特定对象调研 □分析师会议 | | --- | --- | | | 媒体采访 □业绩说明会 | | 调研活动类别 | □新闻发布会 □路演活动 | | | 现场参观 其他 | | 参与单位名称 | 康曼德资本、中泰证券、人保资产、国信证券 | | 时 间 | 2025 年 11 月 20 日下午 14:00-16:00 | | 地 点 | 公司会议室 | | 上市公司接待 | 董事会秘书：黄玉婷 | | 人员姓名 | 证券事务代表：周德伟 | | | 一、内容提要： | | | 1、厂区参观 | | | 2、会议室座谈 | | | 二、主要关注的问题与回复如下： | | | 1、公司的海外市场拓展方向和策略介绍。 | | | 国际市场拓展，公司目前主要聚焦东南亚、中东非、欧洲、 | | | 美洲、印度新澳五大区域，推动高质量销售与服务落地，依托行 | | | 业稀缺的整体解决方案能力、高性价比服务及渠道优势拓展客户。 | | 交流内容 | 后续欧洲、美洲区域订单与业绩有望实现逐步突破，中东非、 | | | 东南亚区域已取得阶段性突破性成果，整体海外业务已进入快速 | | ...

Core Viewpoint - Feilong Co., Ltd. (002536) announced on November 18 that its gross profit margin is expected to increase year-on-year in the first three quarters of 2025 due to several key factors [1] Group 1 - The first reason for the increase in gross profit margin is the relative stability of raw material prices [1] - The second reason is the optimization of product structure, which enhances market competitiveness [1] - The third reason is the strengthening of internal management, including the comprehensive implementation of VA/VE projects, leading to systematic cost reductions through improved production efficiency and refined operations [1]

Core Viewpoint - Dongfang Tantalum Industry has responded to the Shenzhen Stock Exchange's inquiries regarding fluctuations in operating cash flow, rising gross margins, customer and supplier dependencies, and declining export revenues, indicating a steady growth in revenue and net profit from 2022 to 2024, despite a negative cash flow in 2024 [1] Group 1: Cash Flow and Financial Performance - The company's operating cash flow net amounts were 60.75 million, 91.51 million, -61.10 million, and -239.12 million (for January to September 2025), showing a trend of initial growth followed by decline [2] - The negative cash flow in 2024 was primarily due to a 40.29% increase in raw material procurement cash expenditures, amounting to 270.15 million, and a 29% rise in employee compensation to 184.32 million [2] - The company has implemented measures to enhance accounts receivable management and optimize customer structure, with cash collection ratios of 81.64% in 2023 and a decline to 69.55% in 2025 [2] Group 2: Gross Margin and Product Structure - The gross margin for the main business increased from 16.41% to 18.51% from 2022 to 2024, attributed to product structure optimization and cost control [3] - The average procurement price of tantalum ore decreased by 10.88% in 2024, benefiting the company's profit margins due to a lag in price transmission [3] - The company's gross margin is in line with industry averages, slightly below the average by 0.17 percentage points in 2024 [3] Group 3: Export Revenue and Market Expansion - The proportion of foreign sales revenue decreased from 60.21% in 2022 to 35.29% in January to September 2025, influenced by U.S. trade policy changes and successful domestic market expansion [4] - Sales to the U.S. dropped from 26.12% in 2022 to 15.57% in January to September 2025 due to a 25% tariff imposed on tantalum and niobium products [4] - Domestic sales revenue increased from 39.79% to 65.93%, driven by significant demand for high-end products like high-temperature alloys and semiconductor targets [4] Group 4: Customer Concentration and Accounts Receivable - The sales revenue from the top five customers accounted for 48.66%, 35.38%, and 38.12% from 2022 to 2024, indicating a customer concentration level above the industry average [5] - As of September 2025, accounts receivable amounted to 457.93 million, representing 57.47% of revenue, with a high collection rate of over 88% from 2022 to 2024 [5] Group 5: Inventory Management - The company's inventory value increased from 421.76 million to 589.82 million from 2022 to 2025, with a significant portion being raw materials and work-in-progress [7] - The inventory write-down provision was higher than the industry average, reflecting the company's longer production lines and substantial work-in-progress amounts [7] Group 6: Investment and Capacity Expansion - The company plans to raise 1.2 billion for projects related to hydrometallurgy, pyrometallurgy, and high-end products, expecting an annual revenue increase of 3.53 billion post-project completion [9] - The company has established a diversified customer base and has orders totaling 319 million as of September 2025, ensuring capacity absorption [9]

Group 1 - The company achieved a revenue of 299.1 billion yuan in the latest quarter, representing a year-on-year growth of 15% [1] - JD Retail revenue reached 250.6 billion yuan, up 11% year-on-year, driven by accelerated growth in daily necessities and marketing revenue [1] - The number of active users on the platform exceeded 700 million in October, with over 40% growth in both active user count and shopping frequency [1] Group 2 - Non-GAAP net profit was 5.8 billion yuan, with a non-GAAP net profit margin of 1.9%, a decrease of 3.2 percentage points compared to the same period last year [2] - Retail operating profit margin improved from 5.2% to 5.9% year-on-year, attributed to an increase in gross margin and a slight decrease in marketing expenses [2] - The company repurchased 1.5 billion USD worth of shares in the first three quarters of 2025, accounting for 2.8% of the total outstanding shares as of December 31, 2024 [2] Group 3 - The company maintains an "outperform the market" rating, with revenue projections for 2025-2027 adjusted to 1,334.9 billion, 1,433.4 billion, and 1,558.7 billion yuan respectively [2] - Adjusted net profits for 2025-2027 are projected to be 30 billion, 41.5 billion, and 57.4 billion yuan respectively, with slight upward adjustments [2] - The company is expected to optimize supply chain efficiency and improve gross margins, enhancing user experience [2]

Investment Rating - The investment rating for the industry is "Positive" and is maintained [6]. Core Insights - In FY2025Q3 (July 1, 2025 - September 30, 2025), the company achieved revenue of €6.63 billion, representing an 8% year-over-year increase at constant exchange rates. The revenue performance was in line with expectations, with the Adidas brand revenue increasing by 12% [2][4]. - The gross profit margin improved by 0.5 percentage points to 51.8%, driven by lower product and transportation costs, improved business mix, and strong sales [2][4]. - Operating profit margin increased by 1.8 percentage points to 11.1%, while the net profit margin rose by 0.1 percentage points to 7.0% [2][4]. Revenue Breakdown - By region, the Adidas brand saw revenue growth across all markets: Europe (+9%), North America (+1%), Emerging Markets (+11%), Japan/Korea (+6%), and Greater China (+6%). The Adidas brand revenue in these regions grew by 12%, 8%, 13%, 11%, and 10% respectively [5]. - By channel, all channels for the Adidas brand experienced double-digit growth: wholesale (+10%), DTC (+14%), self-operated stores (+13%), and e-commerce (+15%) [5]. - By product category, both footwear and apparel for the Adidas brand achieved double-digit growth, with footwear up by 11% and apparel by 16%. Accessories saw a modest increase of 1% [5]. Inventory and Guidance - As of FY2025Q3, the company's inventory increased by 21% year-over-year to $5.47 billion, attributed to a low base last year and pre-purchases for the World Cup, which is expected to support revenue growth [11]. - The company raised its full-year guidance, projecting a 9% year-over-year revenue increase for FY2025 at constant exchange rates, with the Adidas brand expected to achieve double-digit growth. Operating profit is forecasted to be €2 billion, up from a previous estimate of €1.7 to €1.8 billion [11].

Core Viewpoint - Uni-President China (00220) experienced a decline of over 6%, with a current price of HKD 8.38 and a trading volume of HKD 34.74 million [1] Financial Performance - For the first three quarters, the net profit reached HKD 2.01 billion, representing a year-on-year increase of 23.1% [1] - The net profit for the third quarter alone was HKD 730 million, showing a year-on-year growth of 8.4% [1] Revenue Analysis - According to Huatai Securities, the overall revenue for Q3 2025 remained flat year-on-year [1] - The beverage segment saw a low single-digit decline in revenue for Q3 2025, primarily due to price wars on delivery platforms and industry competition [1] - The food segment experienced a low single-digit growth in revenue for Q3 2025 [1] Profitability Metrics - The gross profit margin improved year-on-year, while the expense ratio decreased, indicating a stable increase in profitability [1]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $533 million, representing a 5% organic growth but an 8% decline reported year over year due to the deconsolidation of IV solutions [5][6] - Adjusted EBITDA increased by 12% to $106 million compared to $95 million last year, while adjusted diluted EPS rose by 28% to $2.03 from $1.59 [18][21] - Gross margin for Q3 was 41%, slightly better than expectations, with improvements attributed to the deconsolidation of IV solutions and a one-time benefit from settling a liability [14][15] Business Line Data and Key Metrics Changes - The consumables business grew 8% reported and 7% organic, driven by new customer implementations and growth in niche markets [7][9] - The IV systems business experienced a 9% reported growth and 8% organic growth, with strong contributions from LVP pumps and dedicated sets [9][10] - The vital care segment saw a significant decline of 52% reported and 4% organic due to the deconsolidation of IV solutions [13] Market Data and Key Metrics Changes - The demand and utilization environment remained attractive across almost all geographies, although growth rates were not as high as the previous year [6] - The capital environment is stable, with customers proceeding with necessary investments [6] Company Strategy and Development Direction - The company aims to build a comprehensive infusion therapy company, focusing on innovation and expanding its product portfolio [26][27] - The strategy includes enhancing patient safety and workflow efficiencies through new product developments and maintaining a competitive edge in the market [12][27] - The company is also focused on optimizing its balance sheet and reducing leverage over time, with a target of around two times levered net debt to EBITDA [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit growth for the consumables and IV systems businesses for the remainder of the year [7][10] - The company is increasing its full-year EBITDA guidance from $380 million-$390 million to $395 million-$405 million, and adjusted EPS guidance from $6.85-$7.15 to $7.35-$7.65 [21][22] - Management acknowledged challenges from tariffs and the absence of one-time benefits in future quarters but remains optimistic about overall performance [22][23] Other Important Information - The company has made significant progress in reducing debt, with $273 million repaid year to date [20] - Free cash flow for the quarter was $28 million, with expectations for improved cash flow generation as restructuring costs decrease [19][56] Q&A Session Summary Question: Sources of strength in consumables growth - Management identified several drivers including market share gains, successful customer implementations, and growth in niche markets like oncology and dialysis [33][34] Question: Expectations for consumables growth in Q4 - Management indicated that while they expect growth, it may not match the sequential lift seen from Q2 to Q3, maintaining a cautious outlook [37] Question: Traction of Duo and Solo infusion systems - Management confirmed that they are taking orders for Solo and noted ongoing discussions in the pump market, with installations still in early stages [38] Question: 2026 tariff exposure outlook - Management reiterated that they do not want to annualize the tariff impact and are actively working on mitigation strategies [41][42] Question: Future gross margin targets and earnings growth - Management discussed the potential for earnings growth through technology value, product mix, and financial leverage, while acknowledging the need to close the gap to their gross margin targets [44][45] Question: Updates on FDA warning letters - Management confirmed ongoing dialogue with the FDA and emphasized their focus on obtaining new product approvals [61][62] Question: Portfolio management within the vital care segment - Management stated they are exploring all available avenues for portfolio optimization but emphasized the importance of not engaging in value-destructive actions [64][66]